1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab antitumor activity in relapsed/refractory classical Hodgkin lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 criteria versus Lugano 2014 classification
    Meeting Abstract

    Moskowitz, C. H.; Chen, R. W.; Armand, P.; Zinzani, P. L.; Vassilakopoulos, T. P.; Goldmacher, G. V.; Lin, J.; Nahar, A.; Balakumaran, A.; Salles, G.
    Blood (2017)

    Fulltext@MSK | Save
  • SETBP1 and NRAS mutations are frequent events in post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) lacking JAK-STAT activating mutations
    Meeting Abstract

    Menghrajani, K.; Rapaport, F.; McNamara, C. J.; Devlin, S. M.; Famulare, C.; Patel, M.; Medina, J.; Sandy, L.; Kosiorek, H.; Singer Weinberg, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Targeting cell non-autonomous MAPK activation as a novel therapeutic strategy in myeloproliferative neoplasms
    Meeting Abstract

    Meyer, S. C.; Ghosh, N.; Stivala, S.; Baerenwaldt, A.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M. S.; Simillion, C.; Chiu, S.; Keller, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Comprehensive genomic profiling (CGP) informs molecular diagnosis, prognosis, and therapeutic decision-making for patients with angioimmunoblastic T-cell lymphoma (AITL)
    Meeting Abstract

    Morley, S.; He, J.; Intlekofer, A. M.; Bailey, M.; Nahas, M.; Heilmann, A.; Chudnovsky, Y.; Fabrizio, D.; Ali, S. M.; Lipson, D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis
    Meeting Abstract

    Mehta-Shah, N.; Teja, S.; Tao, Y.; Cashen, A. F.; Beaven, A.; Alpdogan, O.; Porcu, P.; Wiggin, M.; Song, K. W.; Alzahrani, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Response to the EZH2 inhibitor tazemetostat is independent of cell of origin determined via Hans imunohistochemistry or nanostring lymphoma subtyping test in EZH2 wild-type DLBCL patients
    Meeting Abstract

    McDonald, A. A.; Morschhauser, F.; Ribrag, V.; McKay, P.; Salles, G.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Dickinson, M. J.; Assouline, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Advanced forms of the myeloproliferative neoplasms are associated with chromosomal abnormalities involving 1q and 12q: Implicating MDM2 and MDM4 in disease progression
    Meeting Abstract

    Marcellino, B.; Tripodi, J.; Lu, M.; Kosiorek, H.; Mascarenhas, J.; Rampal, R. K.; Dueck, A. C.; Hoffman, R.; Najfeld, V.
    Blood (2017)

    Fulltext@MSK | Save
  • Melflufen therapy for relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: A report on early efficacy
    Meeting Abstract

    Mateos, M. V.; Bladé, J.; Larocca, A.; Oriol, A.; Rodriguez, P.; Alegre, A.; Cavo, M.; Moreb, J. S.; Paner, A.; Gabrail, N.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, and hematological safety characterization in the BFORE trial
    Meeting Abstract

    Mauro, M. J.; Gambacorti-Passerini, C.; Deininger, M. W.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutiérrez, V. G.; more...
    Blood (2017)

    Fulltext@MSK | Save